Attempts to make trials more diverse aren’t working. To overcome far-reaching inequality and deep distrust, pharma must be educated by, as well as educate, under-served communities

Rare disease patients are organising like never before, turning up the publicity volume and becoming ever more active in driving cures in the lab and even the boardroom

The Astellas head of medical affairs follows up with answers to questions during her virtual keynote earlier this year

The mega congresses of the past look likely to make way for more virtual, focused and, probably, hybrid physical/digital events